ESG401 is Escugen's first ADC in the clinical stage of development. It features an innovative stable and degradable linker that significantly reduces off-target toxicity. Clinical data suggest that ESG401 has a higher tolerable dose than other ADCs targeting the same antigen, with lower incidence and severity of off-target and on-target toxicities, demonstrating a clear safety advantage.

Recently, Shanghai Escugen Biotechnology Co., Ltd. ("Escugen") and Chongqing Sintaho Pharmaceutical Co., Ltd. ("Sintaho") have fully reached a strategic cooperation. Both parties will leverage Escugen's strengths in ADC new drug development, its ADC technology platform represented by EZWi-Fit®, and its Phase III ADC clinical pipeline, as well as Sintaho's advantages in the research and production of functional small molecule compounds, the production of high-activity antitumor APIs, cGMP management, and regulatory registration. Together, they will develop ADC products and services for both domestic and international markets and create a core competitive ADC innovative drug industry chain.